FDA approvals, big-time buyouts, venture capital deals — pick a measure of biopharma success and 2016 probably disappointed.
But there’s hope that next year will be brighter, according to the big annual preview just released by EP Vantage. The promise of a business-friendly Trump administration has some analysts forecasting a return to the record-setting pace of acquisitions that marked biopharma’s recent boom, boosting the valuations of companies big and small.
About the Author Reprints
